limit exceeded
New England Journal of Medicine 351 4 317319. doi 10.1056 and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer".
The new england journal of medicine n engl j med 3606 nejm.org february 5, 2009 conducted in previously untreated patients with metastatic colorectal cancer, the addition of cetuximab
2009 Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. JNCI Journal of the National Cancer Institute 10117,
Correspondence from The New England Journal of Medicine Cetuximab for Metastatic Colorectal Cancer.
Original Article from The New England Journal of Medicine Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. DNA was extracted from tumor tissue for mutation analysis of the KRAS gene see the Supplementary Appendix, available with the full text of this article at NEJM.org. EGFR expression was determined by immunohistochemical assay on tissue microarrays with the use of the EGFR pharmDx Kit Dako according to the manufacturer's instructions.
Di Fiore F , Blanchard F , Charbonnier F , et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007961166-1169 CrossRef Web of Science Medline
Data concerning the concordance of the K-ras mutation status between primary and metastatic colorectal cancer are inconsistent.1,2 We investigated the K-ras mutation status in specimens from 106 patients who had metastatic colorectal